Stocks · News reference
Evotec Partners With Navan To Replace Fragmented Travel And Expense Tools With One Automated Global Platform
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 23, 2026, 7:44 AM
- Checked
- Jul 23, 2026, 7:44 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Evotec Q2 EPS $(0.15) Misses $(0.06) Estimate, Sales $166.802M Miss $212.370M Estimate
Evotec (NASDAQ:EVO) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.06) by 150 percent. This is a 15.38 percent decrease over losses of $(0.14) per share from the same
Read original at benzingaEvotec Affirms FY2026 Sales Guidance of $667.470M-$714.310M vs $673.750M Est
Evotec (NASDAQ:EVO) affirms FY2026 sales outlook from $667.470 million-$714.310 million to $667.470 million-$714.310 million vs $673.750 million estimate.
Read original at benzingaOdyssey Taps Evotec's AI-Driven Discovery Platform To Advance Autoimmune, Inflammatory Disease Programs
Collaboration combines Odyssey's disease biology expertise with Evotec's AI-enabled discovery platform, advanced screening capabilities and proprietary compound libraries to support advancement of Odyssey's
Read original at benzingaOppenheimer Maintains Outperform on Navan, Raises Price Target to $35
Oppenheimer analyst Jed Kelly maintains Navan (NASDAQ:NAVN) with a Outperform and raises the price target from $30 to $35.
Read original at benzingaTD Cowen Maintains Buy on Navan, Raises Price Target to $34
TD Cowen analyst Jared Levine maintains Navan (NASDAQ:NAVN) with a Buy and raises the price target from $29 to $34.
Read original at benzinga